DavidWheeler United KingdomUniversity College London

DavidWheeler
David C WheelerrDavid is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinical scientist interested in chronic kidney disease (CKD). He has participated in the development and delivery of several large-scale clinical trials testing lipid lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study (with Hiddo Lambers Heerspink). David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. Other recent roles include Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) committee. In the UK, he is National Institute of Health Research (NIHR) Specialty Lead for Renal Disorders.
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/4ebc6caaa51e79209f4061cd08dff279.jpg
First Name
David
Last Name
Wheeler
Institution
Country.
United Kingdom

Friday, February 7, 2025

Time Session
2:15 p.m.
3:45 p.m.
Bridging the Clinical Gap: Sustainable Strategies and Innovative Therapies for Global Kidney Health
BKH02
ErangaWijewickrama Chair Sri LankaFaculty of Medicine, University of Colombo
Prof (Dr ) SanjeevGulati Chair IndiaExecutive Director Nephrology and Kidney Transplant, Fortis gp of Hospitals and Adjunct Professor, Manipal University
  • Sustainable Community Approaches to Early CKD Detection
    BKH02-01
    RonaldGansevoort Speaker NetherlandsDept. Nephrology, University Medical Center Groningen
  • Kidney Disease Treatment Gaps Worldwide - Where Are the Solutions?
    BKH02-02
    AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care
  • The Promise of Emerging Therapies in Reducing the Global Kidney Disease Burden
    BKH02-03
    DavidWheeler Speaker United KingdomUniversity College London
  • Co-opting Patients as Partners in Kidney Care: How Do We Do It?
    BKH02-04
    ShilpanjaliJesudason Speaker AustraliaRoyal Adelaide Hospital and University of Adelaide, Australia
  • Co-opting Patients as Partners in Kidney Care: How Do We Do It?
    BKH02-05
    ShyamsundarMuthuramalingam Speaker AustraliaCentral Adelaide Local Health Network
  • Q&A
    BKH02-06
Kesar Hall 202

Saturday, February 8, 2025

Time Session
2:15 p.m.
3:45 p.m.
What’s Next in Kidney Care Research? Innovations and Clinical Trials on the Horizon
SS2
AdeeraLevin Chair CanadaUniversity of British Columbia and Providence Health Care
AndreaViecelli Chair AustraliaUniversity of Queensland
Ajit singhNarula Chair India
  • Novel Trial Designs in Nephrology: Innovations and Structures
    SS2-01
    MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
  • What’s New in Clinical Trials?
    SS2-02
    DavidWheeler Speaker United KingdomUniversity College London
  • Value of Different Outcomes in the Era of Precision Medicine
    SS2-03
    RobertoPecoits Filho Speaker United StatesArbor Research Collaborative for Health
  • Conducting Trials in Low and Middle-income Countries
    SS2-04
    SoumitaBagchi Speaker IndiaProfessor, Department of Nephrology, All India Institute of Medical Sciences, New Delhi
  • Innovations in Pediatric Nephrology Discovery and Clinical Trial Conduct
    SS2-05
    ArpanaIyengar Speaker IndiaST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES, BANGALORE
  • Q&A
    SS2-06
Parijat Hall 201

Sunday, February 9, 2025

Time Session
9 a.m.
10:30 a.m.
HIT! High Impact Clinical Trials – Why and How
HIT2
DavidWheeler Chair United KingdomUniversity College London
Winston Wing ShingFung Chair Hong Kong, ChinaPrince of Wales Hospital, Hong Kong
  • What Have We Learned From CONVINCE?
    HIT2-1
    PeterBlankestijn Oral Abstract Presenter NetherlandsUniversity Medical Center Utrecht
  • Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease
    HIT2-2
    VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia
  • A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
    HIT2-3
    JonathanBarratt Oral Abstract Presenter United KingdomUniversity of Leicester, Leicester, UK
  • Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease
    HIT2-4
    KateBramham Oral Abstract Presenter United KingdomKing's College London
  • Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage
    HIT2-5
    Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India
    SuceenaAlexander Oral Abstract Presenter IndiaChristian Medical College Vellore
Brahmkamal Hall - Plenary Hall